Protective effect of a poly-phitocompound on early stage nephropathy secondary to experimentally-induced diabetes by F. Marotta et al.
JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS Vol. 24, no. 1, 0-0 (2010)
0393-974X (2010)
Copyright © by BIOLIFE, s.a.s.
This publication and/or article is for individual use only and may not be further
reproduced without written permission from the copyright holder.





Diabetes mellitus (DM) is one of the world’s 
fastest growing metabolic disorders that afflicts 
almost 7% of the world population (1). This 
number is expected to double by the year 2030 (2). 
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Diabetic nephropathy (DN) is a severe and life-threatening complication of long-standing diabetes. As 
one of the main causes of end-stage renal disease, the prevention and treatment of DN in early stage, and 
the slowing down of DN progression are of utmost importance and are topics of several ongoing research 
studies. Nutraceuticals endowed with antioxidant-anti-inflammatory properties may offer an opportunity 
of integrative treatment for this condition. Male Wistar rats were randomly assigned to two groups. One 
group of rats (diabetic group) received a single tail-vein injection of STZ compound (50 mg/kg) under light 
anaesthesia. A protective dose of 0.5 ml of 5% dextrose was given intraperitoneally 30 min before the administration 
of STZ. One diabetic group was fed a normal pellet diet (group A) while group B was fed the diet added with DTS 
(panax pseudoginseng, eucommia ulmoides), (Kyotsu Jigyo, Tokyo, Japan) in the proportion of 50/25 (% 
weight/weight), at the dose of 50 mg/kg/day throughout the experimental period. At the end of 8 weeks, 24-hour 
urine was collected for the measurement of the albumin concentration: blood samples were collected for 
serum biochemistry and the rats were sacrificed for kidney measurement of oxidative stress  and histo-
morphological features. Nephrin and Macrophage Chemoattractant Protein-1 (MCP-1) gene expression 
were also assessed by fluorescence real-time quantitative PCR after RNA extraction and cDNA synthesis. 
STZ-treated animals showed significantly increased in lipid peroxidation in the kidney and in proteinuria. 
DTS supplementation did not affect plasma glucose but significantly decreased malonyldialdehyde (MDA) 
plasma level and the overall redox parameters together with a partial mitigation of proteinuria. Histological 
analysis showed also that DTS significantly reduced the glomerular volume together with glomerulosclerosis 
and interstitial fibrosis score (p<0.05), the latter two being correlated to proteinuria (p<0.05). DTS 
supplementation also enabled a reduction of diabetes-induced decrease of nephrin mRNA expression and a 
67% reduction of MCP-1 mRNA up-regulation (p<0.01). Taken altogether, these data show that, besides the 
mandatory control of glycemia, intervention with a nutraceutical with antioxidant and anti-inflammatory 
properties may have beneficial effects when integrated in the mainstream of the therapeutic regimen.
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for general health purposes, might exert a beneficial 
regulation of GSH/GSSG redox status (14-15) while 
conferring a protection against drug-induced DNA 
damage in the liver and kidney of either young or 
aged animals (16). This experimental study was 
designed in view of an integrated approach aimed 
at finding a possible natural protective counteraction 
against diabetes-induced early renal damage. 
MATERIALS AND METHODS
Animals
Adult Wistar rats of either sex (150–180 g) were 
used in these experiments and were maintained under 
controlled standard conditions of light (12/24 h) and 
temperature (26±1oC). Food pellets (crude protein 180 
g/kg; fats 32 g/kg; crude fibre 36 g/kg; carbohydrate 598 
g/kg and metabolic viable energy 301 kcal/100g) and 
tap water were provided ad libitum. For experimental 
purposes animals were fasted overnight but were 
allowed free access to water. All animal procedures 
were performed according to approved protocols and in 
accordance with the recommendations for the proper care 
and use of laboratory animals.
Drugs and reagents
The STZ and reagents were purchased from Sigma 
Chemical Co. (St. Louis, USA) and were of the highest 
commercial grade available.
Preparation of phytotherapeutic compound
DTS (panax pseudoginseng, eucommia ulmoides, 
50/25 (%w/w), Kyotsu Jigyo, Tokyo, Japan) is produced 
under quality-controlled procedure from non-OGM-
modified crops and ISO 9001 and 140001 regulation, 
registered as FOSHU (Food Of Specific Health Use)  and 
it  was kindly donated by the Institute of Health Care 
with Oriental Herbs and Medicine, Tokyo, Japan. This 
compound is composed of palatable tiny grains of medium 
consistency which can be easily mixed with food.
Study design
Male Wistar rats, 12 weeks old, weighing 220-250 
g, were randomly assigned to two groups. One group 
of rats (diabetic group) received a single tail-vein 
injection of STZ (50 mg/kg) under light anaesthesia 
with diethyl ether after 18 h of fasting, as described 
by the National Institute of Diabetes and Digestive 
and Kidney Diseases Consortium for Animal Models 
of Diabetic Complications’ protocol (available from 
http://www.amdcc.org). STZ was dissolved in a citrate 
buffered solution [0.15 M citric acid and 0.25 M sodium 
Hyperglycemia associated with diabetes impairs 
the natural antioxidative mechanisms through non-
enzymatic glycosylation of the antioxidant  enzymes 
(3) while the increased degradation of glycated 
proteins leads to enhanced production of reactive 
oxygen species (ROS) (4). ROS are known to play 
a major role in a variety of physiologic and disease-
related processes and have been clearly implicated in 
the pathophysiology of diabetic nephropathy (5). A 
number of experimental and clinical studies suggest 
that increased oxidative stress may also contribute to 
the initiation and progression of diabetic nephropathy 
(6-7). Non-enzymatic glycation of long-lived 
structural proteins is one of the mechanisms involved 
in the pathogenesis of this complication (8-9) which 
is strongly associated with worsening of the whole 
clinical condition and premature death, mostly 
related to cardiovascular events. Therefore, the 
current challenge in the care of diabetes is targeted 
to design novel approaches aimed at minimizing the 
development of such complications. It develops in 
5-10% of Caucasian patients with NIDDM, whereas 
among other racial groups the incidence of renal 
insufficiency due to NIDDM may be 50% or more 
since other genetic factors are likely to be involved. 
From the available scientific evidence, it would 
appear that the best predictive marker for vascular 
complications is represented by microalbuminuria 
(10) which is significantly linked with mortality and 
morbidity, including overcoming glomerulopathy 
(11). Indeed, once microalbuminuria appears, the 
risk of nephropathy remarkably and predictably 
increases (12). In this respect, nephrin, a specific 
podocyte protein, essential to maintain the integrity 
of the interpodocyte slit membrane structure and 
filtration barrier, seems also to be involved. It has 
been found that in diabetic nephropathy, the synthesis 
of the splice variant isoform of nephrin lacking a 
transmembrane domain causes a urinary loss of 
nephrin leading to a decrease of protein level. 
Studies have shown that podocyte damage and 
decrease of nephrin expression are present even at the 
early stage of DN and play a key role in accelerating 
the development of DN especially when the levels of 
nephrin expression are downregulated and there is an 
increase in desmin expression (13). 
We have recently shown that DTS, a novel 
functional food supplement used in clinics safely 
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phosphate, (pH 4. 5). Approximately 80% of the STZ-
treated rats developed stable hyperglycaemia. A protective 
dose of 0.5 ml of 5% dextrose was given intra-peritoneally 
30 min before the administration of STZ. Only animals 
with blood glucose levels = 250 mg/100 ml were included 
in further experiments. All animals survived the study 
without any sign of illness or of apparent exhaustion 
during the course of the study.
One diabetic group was fed a common pellet diet (group 
A) while group B was fed the same diet supplemented 
with DTS at the dose of 50mg/kg/day throughout the 
experimental period. Another group of healthy animals 
received an equivalent volume of citrate buffer solution 
alone and were fed a normal diet representing a control 
group (C group), while a separate healthy control group 
of rats was fed a diet supplemented with DTS to check its 
effect in healthy animals.
Specimen collection
At the end of the 8th week, a 24-hour urine sample was 
collected through metabolic cages. Then the rats were 
anesthetized by sodium pentobarbital (50 mg/kg, ip), and 
blood samples were collected for serum biochemistry. 
Kidneys were completely perfused with normal saline 
before their removal. Part of the left kidney was immersed 
in 10% neutral formalin solution and 2.5% glutaraldehyde 
for patho-morphology analysis. The other part was divided 
into pieces and stored at –70 C for future quantitative 
real-time polymerase chain reaction (PCR). 
Determination of plasma glucose and creatinine
Plasma glucose was measured by a colorimetric 
method using glucose oxidase (Boehringer Mannheim, 
Germany) in a Hitachi 917 autoanalyser. Serum creatinine 
level was measured by the enzymatic colorimetric method 
(17).
Determination of urinary albumin excretion 
Urinary albumin concentration was measured by 
nephelometry using anti-mouse albumin antibody (ICN 
Pharmaceuticals, Aurora, USA). Results were normalized 
to the urinary creatinine levels (18).
Biochemical assessment in kidney tissue 









, pH 7.0, plus 29.2 mg ethylen
ediaminetetraacetic acid (EDTA) in 100 ml of distilled 
water and 10.0 mg digitonin in 100 ml of distilled water, 
final volume, 2,000 ml) to produce a homogenate. The 
homogenates were then centrifuged at 10,000 × g for 10 
min at 4°C.
Glutathione peroxidase (GPx) activity was assayed 
at 340 nm by spectrophotometry and the amount of the 
enzyme converting 1 µmol GSH per min was taken as 1 
activity unit (19). Catalase activity was measured in the 
cell cytosol fraction and was calculated at 240 nm by 




decomposition at 240 nm with 




being 43.6 M-1 





min was taken as 1 activity unit (20). For determination 
of malondialdehyde, the kidneys were homogenized in ice 
cold 20 mM Tris-HCl buffer (pH 7.4). The homogenates 
were then centrifuged at 10,000 × g for 10 min at 4°C. 
Concentration of malondialdehyde was measured by the 
thiobarbituric acid test. Briefly, 1 mM EDTA (Sigma, St. 
Louis, MO, USA) was added to a 0.5 ml haemolysate and 
was mixed with 1 ml cold 15% (w/v) trichloroacetic acid 
to precipitate proteins. The supernatant was treated with 1 
ml 0.5% (w/v) thiobarbituric acid in a boiling water bath 
for 15 min. After cooling, the absorbance was read at 535 
nm and the concentration of thiobarbituric acid reactive 
substance was calculated by using malondialdehyde as a 
standard. Results were expressed as nMol thiobarbituric 
acid reactive substances/mg of protein (21). Protein 
concentration was determined by the Bradford method 
using bovine serum albumin as a standard (22). To 
determine carbonyl level in proteins, 1 ml of haemolysate 
was placed in a glass tube and 3 ml of 8 mM 2, 4-
dinitrophenylhydrazine in 3 M HCL was added. The tubes 
were incubated for 50 min at 37°C in the dark and vortexed 
every 10 min. Three ml of 25% (w/v) trichloroacetic acid 
was then added and the tube was left on ice for 8 min 
and then centrifuged for 3 min in a tabletop centrifuge 
to collect the protein precipitates. This pellet was washed 
using 3 ml 15% trichloroacetic acid followed by two 
washes with 4 ml of ethanol-ethyl acetate (1:1), (v/v). The 
final precipitate was dissolved in 2 ml of 5 M guanidine 
hydrochloride solution and was incubated for 15 min at 
37°C with frequent mixing, and any insoluble materials 
were removed by repeated centrifugation. 
Histological study
All formalin-fixed kidney sections (3 μm) were 
stained with hematoxylin (HE) and periodic acid-schiff 
(PAS). Digital images of glomeruli and interstitial areas 
were obtained by light microscopy (magnification, 
×400). The glomerular cross-sectional area (AG) was 
measured in 50 glomerular profiles per rat by using 
computerized image analysis system (Olympus image-
analyser, Japan). The glomerular volume (VG) was then 
calculated as: VG = β/K[AGI3/2, where β = 1.38 is the 
size distribution coefficient and K = 1.1 is the shape 
coefficient for glomeruli idealized as a sphere. 
The glomerulosclerosis index (GSI) in each glomerulus 
was scored semi-quantitatively as follows: 0, no sclerosis; 
1, sclerosis in <25% of glomerulus; 2, sclerosis in 25%–
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to calculate the corresponding gene copy number. The 
result was expressed as the ratio of target gene copy over 
housekeeping gene (GAPDH) copy.  
Statistical analysis
Data was analyzed by ANOVA using Duncan’s post-
hoc test for comparisons among means at p=0.05 when 
appropriate. If the data were not normally distributed, we 
used the Kruskal-Wallis test (non-parametric analysis of 
variance) followed by Dunn's multiple comparisons test. 
Statistically, p < 0.05 was considered significant.
RESULTS
Plasma and urine biochemistry
At the end of the 8th week, the biochemical 
parameters indicated that the STZ injection 
produced diabetic animals with low levels of insulin 
production, and high levels of plasma glucose and 
glucose excretion compared to healthy control rats 
(p<0.01, Table I). Oxidative stress was also induced 
in the STZ-treated animals with increased lipid 
peroxidation as compared to control (p<0.001). 
DTS supplementation (group B) did not affect 
plasma glucose but it significantly decreased MDA 
plasma level (p<0.05 vs untreated diabetic rats). 
STZ had no significant effect on creatinine while 
it caused a significant proteinuria (p<0.01, Table 
I). This abnormality was partially mitigated by co-
administration of DTS (p<0.05 vs untreated diabetic 
rats). 
Renal tissue biochemistry  
Table II shows the effects of administration of 
DTS on the levels of kidney MDA, GSH and CAT 
in diabetic rats. STZ-induced diabetic rats showed 
a significant depletion of GSH and CAT  with 
increased MDA (p<0.01; B vs C: p<0.05). The level 
of non-enzymatic and enzymatic antioxidants in 
both DTS-treated groups were found to be higher 
than the untreated rats with significantly lower 
MDA generation (p<0.05). In particular, DTS 
administration brought about a full restoration of all 
the above redox parameters (p<0.001).  
Histological findings
The most consistent feature of glomerular lesion 
in diabetic rats was represented  by thickening of 
the basement membrane, mesangial expansion and 
50% of glomerulus; 3, sclerosis in >50% of glomerulus. 
To evaluate interstitial fibrosis, 20 fields for each section 
were assessed on PAS-stained sections (×200). Semi-
quantitative analysis in each field was assessed as follows: 
0, no fibrosis; 1, fibrosis in <10% area; 2, fibrosis in 
10%–25% area; 3, fibrosis in 25%–50% area; 4, fibrosis in 
>50% area. Averages of glomerulosclerosis and interstitial 
fibrosis scores were calculated. All measurements and 
scoring were performed on blinded slides.
Assessment of Nephrin and Macrophage Chemoattractant 
Protein-1 (MCP-1) gene expression in the kidney
RNA extraction and cDNA synthesis. Frozen renal 
tissues samples were homogenized and total RNA 
was extracted with Trizol (Invitrogen, USA) one-step 
extraction protocol. The extracted RNA was quantitatively 
assessed by agarose gel electrophoresis and tested by 
spectrometry for quantity
At a wavelength of 280 nm.
The OD260/OD280 ratios were within the range of 
1.8–2.0. Two � of total RNA were reverse transcribed 
in the presence of random primers and M-MLV reverse 
transcriptase (Promega) according to the following 
sequence: 70� for 5 min, followed by 37� for 60 min, 
and 75� for 15 min. Reverse transcription reaction 
system (BioGeneTech Co., Seoul) had a total volume of 
20 μl (23).  
Fluorescence real-time quantitative PCR
1000 ng mRNA sample was accurately added into 
the reverse transcription system with the resulting 
cDNA as standard. It was diluted 10-fold to establish 
the standard curve. The real-time PCR was carried out 
in ABI PRISM 7000 HT (Applied Invitrogen 11744-
100, USA) in 25 μl reaction system: 12.5 μl SYBR 
Premix Ex TaqTM (2×Conc.), 0.5 μl ROX reference 
dye (50×), 0.5 μl PCR forward primer (10 μmol/L), 0.5 
μl PCR reverse primer (BioGeneTech Co., Seoul). For 
nephrin mRNA quantification, primers (rNEF-Q1: 5'- 
TAATGTGTCTGCGGCCCAG-3' and rNEF-Q1R: 5'- 
TGTTGGTGTGGTCAGAGCCA-3') and TaqMan probe 
(rNEF-TAQ1: 5'-CCCTCTTCAAATGCACGGCCACC-
3') were synthesized. For MCP-1 quantification: 
sense 5'-TGTGCCTGCTGCTCAC T-3', antisense 5'-
GTTTGGGTTTGCTTGAA-3' (product size 368 bp,); 
β-actin sense 5’-AAGAGAGGCATCCTCACCGTG-3', 
antisense 5’-TACATGGCTGGGGTGTTGCTG-3' 
(product size 625 bp).The following two-step PCR 
procedure was applied: pre-denaturation at 95°C for 10 
seconds and 45 cycles for 5 seconds at 95°C and 31 seconds 
at 60–63°C. Standard curves for target genes and internal 
reference gene were built under the same conditions, and 
the cycle threshold (Ct) values of the samples were used 
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score (r=0.63, p<0.05) on the other one. DTS in 
healthy control rats did not produce any substantial 
histological change.
Assessment of nephrin and Macrophage 
Chemoattractant Protein-1 (MCP-1) gene expression 
in the kidney
Nephrin mRNA expression in diabetic rats was 
lower than that of control rats (66%, p<0.05). DTS 
significantly restored nephrin mRNA expression in 
diabetic rats (Fig. 2). MCP-1 mRNA expression 
in the renal cortex was significantly increased in 
diabetic rats as compared with that of control rats 
(288%, p<0.01).  Over-expression of MCP-1 in 
diabetic rats was significantly reduced by treatment 
with DTS (67%, p<0.05). There was a significantly 
negative correlation between nephrin and MCP-1 
mRNA (r: –0.75, p<0.01) and 24-hour proteinuria 
with either mRNA levels of nephrin (r=–0.63, 
p<0.01) or MCP-1 (r=0.59, p<0.01). 
interstitial sclerosis. The glomerulosclerosis score 
in diabetic rats was significantly higher than that of 
control rats (1.04±0.08 vs 0.15±0.03, p<0.01, Fig. 
1). DTS  significantly reduced glomerulosclerosis 
in diabetic rats (0.71±0.09,  p<0.05 vs untreated 
DM. Concomitantly, DTS treatment significantly 
decreased (p<0.05) the over 50% increase of 
glomerular volume observed in diabetic rats 
(p<0.001 vs healthy control). Interstitial fibrosis 
was focal and mild but the interstitial fibrosis 
score was higher in untreated diabetic rats than in 
controls (0.44±0.02 vs 0.11±0.03, p<0.01; Fig. 1). 
Interstitial fibrosis was significantly reduced by 
DTS compared (0.29±0.04, p<0.05) with that of 
untreated diabetic rats. DTS did not produce any 
significant plasma or tissue biochemical changes 
in healthy control rats (data not shown). There was 
a significant correlation among 24-hour urinary 
protein on the one side and, glomerulosclerosis 
score (r=0.61, p<0.05), and interstitial fibrosis 
Table I. Plasma and urinary measurements in diabetic rats: effect of DTS supplementation. 
A B C
Glucose (mg/dl)  268 ± 8* 272 ± 11* 69 ± 3
Creatinine (mg/dL) 0.7± 0.1 0.7 ± 0.2 0.6 ± 0.1
U. albumin (mg/24h) 0.4 ± 0.1* 0.3 ± 0.2** 0.2 ± 0.1
Effect of DTS phytocompound on plasma and urinary parameters in STZ-induced diabetes. *p<0.01 DTS treated group 
(group B) vs control animals (group C); ** p<0.05 vs untreated animals (group A)
 







A 2.8 ± 0.7* 0.1 ± 0.05* 0.37 ± 0.3*
B 3.9 ± 0.9** 0.2 ± 0.1** 0.15 ± 0.3**
C  4.4 ± 0.8 0.3 ± 0.1 0.13 ± 0.1
Effect of DTS phytocompound on oxidative stress parameters in renal tissue in STZ-induced diabetes. *p<0.01 DTS 
treated group (group B) vs control animals (group C); ** p<0.05 vs untreated animals (group A).
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leading to cardiovascular derangement and end-stage 
renal disease in the Western countries and in Asia, 
particularly in Japan. Early alterations in diabetic 
nephropathy consist in glomerular hyperfiltration 
hypertrophy also involving the tubular epithelium 
with consequent microalbuminuria. Although it is 
not fully clear how the structural changes bring about 
the microalbuminuria, the damage to the glomerular 
basement membrance (GBM) and mesangium 
is likely to result from the decreased density and 
sulfation of heparan sulfate proteoglycans (24). This 
in turn causes a loss of charge selectivity, and leakage 
of serum albumin across the barrier (25). Injury 
to the capillaries might result from multifactorial 
components, such as hemodynamic factors (26), 
glomerular hyperfiltration due to vasoactive 
control system abnormalities (27) and others. 
However, whatever the mechanisms are, the final 
GBM damage is the most consistent feature which 
develops during the glomerulopathy. These subtle 
changes are followed by thickening of glomerular 
basement membrane, accumulation of extracellular 
matrix, and overt proteinuria, eventually leading 
to glomerulosclerosis and end-stage renal disease 
(28). This sequel of events has been regarded as the 
DISCUSSION
Diabetic nephropathy is a complication occurring 
in 30-50% of patients with type 2 diabetes after 
Fig. 1. Effect of STZ-induced diabetes and phyto-
compound treatment on glomerular parameters. Effect 
of DTS phytocompound on glomerular parameters in 
STZ-induced diabetes. GV: glomerular volume, GSI: 
glomerulosclerosis index; IF: interstitial fibrosis. 
*p<0.01 DTS treated group (group B) vs control animals 
(group C); ** p<0.05 vs untreated animals (group A)
Fig. 2. MCP-1 gene expression in renal tissue in STZ-
induced diabetes: effect of nutraceutical treatment. Effect 
of DTS phytocompound on MCP-1 gene expression in 
renal tissue in STZ-induced diabetes. * p<0.01 DTS 
treated group (group B) vs control animals (group C); ** 
p<0.05 vs untreated animals (group A)
Fig. 3. Modifications of nephrin gene expression in 
renal tissue in STZ-induced diabetes: effect of DTS 
nutraceutical. Effect of DTS phytocompound on nephrin 
gene expression in renal tissue in STZ-induced diabetes. 
*p<0.05 DTS treated group (group B) vs control animals 
(group C); ** p<0.01 vs untreated animals (group A)
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result of an immunological-inflammatory process. 
Indeed,  the presence of monocyte chemoattractant 
peptide-1 (MCP-1), IL-1β, adhesion molecules, and 
macrophage infiltration in kidney has been reported 
in diabetic patients and animal diabetic models. 
MCP-1, a typical chemokine, recruits inflammatory 
cells to renal tissue and triggers inflammatory 
processes such as the stimulation of other cytokines 
and growth factors, which ultimately leads to kidney 
injury by induction of α1-type IV collagen synthesis. 
In this respect, STZ-induced diabetes provides a 
relevant model of endogenous chronic oxidative 
stress and hyperglycemia which, in turn promotes 
oxidative stress and up-regulates the expression of 
transforming growth factor-beta 1 (TGF-β1) in the 
glomeruli (29). Moreover, monocyte/macrophages 
glomerular infiltration, and glomerular hypertrophy 
bring about progressive damage of podocytes which 
are characterized by high differentiation but limited 
dividing ability and which are the major synthesis 
site of inflammatory cytokines, vascular endothelial 
growth factor, and chemokines receptors (30). In 
the present study DTS supplementation significantly 
mitigated oxidative stress in the kidney of STZ-treated 
rats. Furthermore, despite the overall diabetic features 
remaining unaffected (hyperglycemia, low insulin 
level), the supplemented nutraceutical significantly 
improved  the proteinuria by a mechanism not yet 
fully understood which warrants further studies. In 
particular, proteinuria was directly correlated with 
GSI and IFI in untreated rats, while both scores 
significantly improved in DTS-treated rats. 
DTS also mitigated the significant decrease of 
nephrin mRNA expression which was inversely 
correlated to proteinuria. It is generally accepted that 
podocyte damage is inversely correlated with down 
regulation of nephrin expression which suggests 
a switch-over to intermediate filament expression 
(31). Indeed, as a consequence of down regulation 
of nephrin expression, the structure of slit membrane 
in podocytes is destroyed and this represents one of 
the hallmarks of renal progressive dysfunction in 
an experimental setting (32) and in patients with 
diabetic nephropathy (33). It will be worthwhile 
in future studies to examine the possible effect of 
DTS on podocyte integrity. Although we did not 
conduct a detailed and specific morphological study 
on podocyte status, our study suggests that DTS 
could partially prevent the loss of podocytes and 
subsequently reduce urinary albumin excretion. 
The effect of DTS on podocyte integrity should 
be the focus of our new studies. Conversely, DTS 
significantly reduced glomerular expression of MCP-
1 through a likely anti-oxidant/anti-inflammatory 
property exerted by the main components of the 
phytocompound (14-15), possibly resulting in nitric 
oxide-induced vasodilation as recently suggested for 
eucomnia ulmoides (34), although this hypothesis 
needs experimental confirmation.
While the primary prevention of nephropathy, 
and indeed of most diabetic complications, resides 
in the control of hyperglycemia and genetic 
predisposition to hypertension, micro-albuminuria 
and cardiovascular disease may be further 
complication factors in the course of this disease. 
The present study shows that DTS nutraceutical may 
offer a promising option to be further explored in 
clinical practice in a foreseeable integrative care of 
diabetic patients.
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